PYC Therapeutics (ASX: PYC) — Company Overview, News & Financial Data
PYC Therapeutics develops RNA therapeutics for genetic diseases, with a focus on precision medicines addressing underlying causes.
PYC Therapeutics
PYC Therapeutics is a clinical-stage biotechnology company that develops novel RNA therapeutics using a proprietary cell-penetrating peptide drug delivery platform to treat severe genetic diseases. The company combines scientific research, clinical insights, and targeted drug delivery technology to address monogenic conditions with limited or no existing treatment options. Its pipeline focuses on precision RNA therapies for inherited ocular and renal conditions, including retinitis pigmentosa type 11, autosomal dominant optic atrophy, and autosomal dominant polycystic kidney disease. Headquartered in Australia, the company conducts preclinical and clinical development programs designed to restore normal protein expression and modify disease progression in targeted patient populations.
Snapshot
Operations
Products and/or services of PYC Therapeutics
- Cell-Penetrating Peptide Drug Delivery Platform: Proprietary drug delivery technology utilizing cell-penetrating peptides conjugated to RNA therapeutics to enable intracellular delivery across cell membranes, overcoming structural barriers to enhance therapeutic potency inside targeted cells for severe monogenic diseases.
- Retinitis Pigmentosa Type 11 Therapeutics: Clinical-stage RNA investigational therapy targeting haploinsufficiency caused by PRPF31 gene mutations, designed to restore functional protein production inside retinal cells and halt progressive vision loss in affected ophthalmic patients globally.
- Autosomal Dominant Optic Atrophy Therapeutics: Investigational precision RNA therapeutic program addressing optic nerve atrophy driven by OPA1 gene mutations, aiming to boost functional OPA1 protein expression and preserve retinal ganglion cell structure and vision.
- Autosomal Dominant Polycystic Kidney Disease Therapeutics: Targeted RNA drug candidate designed to increase polycystin-1 protein expression by modulating PKD1 gene output, aiming to reduce cyst growth and preserve long-term kidney function in patients with polycystic kidney disease.
- Phelan-McDermid Syndrome Therapeutics: Preclinical RNA therapeutic candidate targeting SHANK3 gene haploinsufficiency, formulated with cell-penetrating peptides to deliver functional protein-restoring oligomers into central nervous system tissues for treating neurodevelopmental genetic impairment.
- Monogenic Disease Research and Clinical Development: Translational biotechnology operations including preclinical screening, non-human primate pharmacology studies, and multi-center clinical trials evaluating peptide-conjugated oligonucleotide therapeutics across targeted genetic indications in ophthalmology, nephrology, and neurology.
PYC Therapeutics executive team
- Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.)CEO & Executive Director
- Mr. Garrett BrayChief Operating Officer
- Mr. Sean HouthuysenGeneral Counsel
- Dr. Sri MudumbaChief Research & Development Officer
- Dr. Paula CunninghamChief Pre-Clinical Research Officer
- Dr. Janya GrainokChief Discovery Officer
- Mr. Aaron KiddChief Commercial Officer
- Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A.Company Secretary